title: Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses in HIV-2-infected and in HIV-2-exposed but uninfected individuals in Guinea-Bissau.
abstract: Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses were determined in cultures of peripheral blood mononuclear cells from HIV-2-exposed uninfected individuals, HIV-2-infected individuals and HIV-negative controls in Guinea-Bissau. Increased HIV-2-specific T lymphocyte proliferative responses were detected in both groups compared to HIV-negative controls (healthy HIV-uninfected individuals without known exposure to an HIV-infected person); five out of 29 of the HIV-2-exposed uninfected and half (16 of 32) of the HIV-2-infected individuals had stimulation indexes >2, compared to one out of 49 of the HIV-negative controls (P = 0.003 and P < 0.0001, respectively). The exposed uninfected individuals had reactivity to a HIV-2 V3-peptide corresponding to amino acids 311-326 of the envelope glycoprotein, while the HIV-2-infected people reacted mainly to HIV-2 whole viral lysate. Thus, this study demonstrates a high degree of HIV-2-specific T helper cell activity, as measured by lymphocyte proliferation, in HIV-2-exposed uninfected individuals as well as in HIV-2-infected subjects. These immune responses could be important for resistance to the infection and for the control of established infection and, thus, play a role in the lower transmission and progression of HIV-2 compared to HIV-1.
authors.affiliation: Swedish Institute for Infectious Disease Control and the Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden. soren.andersson@orebroll.se
authors.forename: S
authors.initials: S
authors.lastname: Andersson
authors.forename: O
authors.initials: O
authors.lastname: Larsen
authors.forename: Z
authors.initials: Z
authors.lastname: Da Silva
authors.forename: H
authors.initials: H
authors.lastname: Linder
authors.forename: H
authors.initials: H
authors.lastname: Norrgren
authors.forename: F
authors.initials: F
authors.lastname: Dias
authors.forename: R
authors.initials: R
authors.lastname: Thorstensson
authors.forename: P
authors.initials: P
authors.lastname: Aaby
authors.forename: G
authors.initials: G
authors.lastname: Biberfeld
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D016022:Case-Control Studies; D018929:Cell Culture Techniques; D049109:Cell Proliferation; D004198:Disease Susceptibility; D005260:Female; D006169:Guinea-Bissau; D015658:HIV Infections / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D011247:Pregnancy; D011446:Prospective Studies; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000821:virology
chemical_list: D000914:Antibodies, Viral
references.citation: AIDS. 2000 Mar 10;14(4):441-8
references.pmid: 10770548
references.citation: AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1521-30
references.pmid: 9840285
references.citation: Vaccine. 2000 Sep 15;19(2-3):298-307
references.pmid: 10930685
references.citation: J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):257-63
references.pmid: 10969350
references.citation: Arch Intern Med. 2000 Nov 27;160(21):3286-93
references.pmid: 11088091
references.citation: J Clin Invest. 2001 Feb;107(3):341-9
references.pmid: 11160158
references.citation: J Clin Invest. 2001 May;107(10):1303-10
references.pmid: 11375420
references.citation: AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1155-65
references.pmid: 11522185
references.citation: Immunol Lett. 2001 Nov 1;79(1-2):3-13
references.pmid: 11595284
references.citation: J Infect Dis. 2002 Apr 1;185(7):905-14
references.pmid: 11920314
references.citation: J Reprod Immunol. 2003 Feb;58(1):79-91
references.pmid: 12609527
references.citation: J Gen Virol. 2003 May;84(Pt 5):1287-99
references.pmid: 12692296
references.citation: J Virol. 2004 Jul;78(13):7016-22
references.pmid: 15194778
references.citation: N Engl J Med. 1983 Jul 7;309(1):13-7
references.pmid: 6602294
references.citation: J Virol. 1987 Jun;61(6):2017-23
references.pmid: 3033328
references.citation: AIDS. 1988 Jun;2(3):195-9
references.pmid: 3134913
references.citation: AIDS Res Hum Retroviruses. 1988 Jun;4(3):175-86
references.pmid: 2840105
references.citation: J Immunol. 1989 Feb 15;142(4):1166-76
references.pmid: 2783706
references.citation: J Clin Invest. 1989 Apr;83(4):1198-203
references.pmid: 2703528
references.citation: J Immunol. 1990 Dec 15;145(12):4348-54
references.pmid: 2258623
references.citation: AIDS. 1991 Jul;5(7):859-63
references.pmid: 1892591
references.citation: J Acquir Immune Defic Syndr. 1992;5(1):25-30
references.pmid: 1738085
references.citation: J Infect Dis. 1992 Jun;165(6):1012-9
references.pmid: 1533867
references.citation: Eur J Immunol. 1992 Sep;22(9):2211-7
references.pmid: 1381309
references.citation: J Acquir Immune Defic Syndr. 1993 Aug;6(8):941-8
references.pmid: 8315578
references.citation: AIDS Res Hum Retroviruses. 1993 May;9(5):431-8
references.pmid: 8318269
references.citation: J Virol. 1993 Aug;67(8):5035-40
references.pmid: 8331739
references.citation: AIDS. 1993 Jul;7(7):989-93
references.pmid: 8357558
references.citation: J Immunol. 1993 Sep 15;151(6):3361-9
references.pmid: 7690804
references.citation: JAMA. 1993 Nov 3;270(17):2083-6
references.pmid: 8147962
references.citation: AIDS. 1993 Oct;7(10):1389-91
references.pmid: 8267915
references.citation: J Immunol. 1994 Feb 15;152(4):1952-9
references.pmid: 8120399
references.citation: J Clin Invest. 1994 Mar;93(3):1293-7
references.pmid: 8132769
references.citation: Lancet. 1994 Apr 16;343(8903):943-6
references.pmid: 7909009
references.citation: Science. 1994 Sep 9;265(5178):1587-90
references.pmid: 7915856
references.citation: Nature. 1995 Jan 12;373(6510):117-22
references.pmid: 7529365
references.citation: Nature. 1995 Jan 12;373(6510):123-6
references.pmid: 7816094
references.citation: AIDS. 1994 Oct;8(10):1391-5
references.pmid: 7818809
references.citation: Virology. 1995 Jan 10;206(1):673-8
references.pmid: 7831824
references.citation: Clin Immunol Immunopathol. 1995 Aug;76(2):135-41
references.pmid: 7614732
references.citation: AIDS. 1995 Jun;9(6):555-9
references.pmid: 7662192
references.citation: J Immunol. 1999 Jan 1;162(1):540-9
references.pmid: 9886431
references.citation: J Virol. 1999 Jan;73(1):436-43
references.pmid: 9847349
references.citation: J Hum Virol. 1998 Nov-Dec;1(7):457-68
references.pmid: 10195267
references.citation: AIDS. 1999 Apr 16;13(6):701-7
references.pmid: 10397565
references.citation: AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):957-62
references.pmid: 10445807
references.citation: J Infect Dis. 1999 Oct;180(4):1116-21
references.pmid: 10479138
references.citation: Nat Med. 1995 Jan;1(1):59-64
references.pmid: 7584954
references.citation: J Med Virol. 1995 Oct;47(2):139-44
references.pmid: 8830117
references.citation: J Infect Dis. 1996 Nov;174(5):977-85
references.pmid: 8896498
references.citation: J Virol. 1997 Jul;71(7):4981-4
references.pmid: 9188561
references.citation: Nat Med. 1997 Nov;3(11):1250-7
references.pmid: 9359700
references.citation: Science. 1997 Nov 21;278(5342):1447-50
references.pmid: 9367954
references.citation: AIDS. 1997 Dec;11(15):1815-22
references.pmid: 9412699
references.citation: J Infect Dis. 1998 Jan;177(1):65-71
references.pmid: 9419171
references.citation: AIDS. 1997;11 Suppl A:S99-107
references.pmid: 9451973
references.citation: J Virol. 1998 Mar;72(3):2439-48
references.pmid: 9499105
references.citation: J Virol Methods. 1998 Feb;70(2):139-51
references.pmid: 9562408
references.citation: AIDS. 1998;12 Suppl A:S133-40
references.pmid: 9632994
references.citation: AIDS Res Hum Retroviruses. 1998 Jun;14 Suppl 2:S143-7
references.pmid: 9672231
references.citation: AIDS. 1998 Sep 10;12(13):1707-14
references.pmid: 9764792
references.citation: J Infect Dis. 2000 May;181(5):1581-9
references.pmid: 10823757